RANCHO SANTA MARGARITA, Calif., Jan. 9, 2003 (PRIMEZONE) -- BioCurex, Inc. (OTCBB:BOCX) announces further developments relating to its licensing agreement with BioKinetix, a company being acquired by RJV Networks, Inc. (OTCBB:RJVN).
BioCurex and RJV Networks (through BioKinetix) are behind the development of a new therapeutic product, which experts believe will arrest the development of and replication of cancerous cells that cause the growth of malignant tumors.
BOCX's proprietary technology has identified a New Widespread Cancer Marker Molecule named RECAF. Cancer "markers" are molecules that appear on cancer cells but not on normal cells and have been hailed as extremely important in cancer research since they can by used to detect (diagnose) and then specifically target cancer cells (therapy) -- offering the potential to provide treatment of cancer by delivering antibodies to the targeted cancerous cells. The diagnostic market for the few cancer markers known is over two billion dollars per year.
RJVN and BioKinetics have proprietary technology for developing "superantibodies," an enhancement of antibody technology that makes ordinary antibodies much more lethal. The combination of anti-RECAF antibodies from BioCurex with the superantibody technology from RJVN -- BioKinetics is expected to produce a powerful therapeutic agent to combat most types of cancer.
If the antibodies prove to be cancer cell specific, it is unlikely that there would be any adverse side effects. This lack of toxicity should accelerate testing and approval process.
Dr. Moro, President of Biocurex, stated: "Our ultimate goal is to fight cancer. We have the cancer marker that identifies the cancer cells and RJV Networks-BioKinetix has the superantibody technology to kill them. It is only natural that we join forces in the battle against this horrible disease. I see tremendous potential for success in this joint effort."
Dr. John Todd, President of BioKinetix Corporation, stated that BioKinetix Corporation's mission is to acquire intellectual property rights for existing products and intellectual property. "Then, through a series of collaborative relationships, we will facilitate the development of a new generation of monoclonal antibodies (termed "Superantibodies"), which will have a significantly improved therapeutic potency as anticancer agents."
Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.